Dudediligence.

QuidelOrtho Corporation

QDELNASDAQ · In Vitro & in Vivo Diagnostic Substances
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$727.1MSep ’24$707.8MDec ’24$692.8MMar ’25$613.9MJun ’25$699.9MSep ’25$723.6MDec ’25$619.8MMar ’26$630.9MJun ’26
Net income, by quarter
−$19.9MSep ’24−$178.4MDec ’24−$12.7MMar ’25−$255.4MJun ’25−$733.0MSep ’25−$130.7MDec ’25−$91.8MMar ’26−$92.9MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$1.70B$3.27B$3.00B$2.78B$2.73B
Operating income$906.0M$843.7M$139.1M−$1.96B−$919.2M
Net income$704.2M$548.7M−$10.1M−$2.05B−$1.13B
Operating cash flow$805.9M$885.3M$280.2M$83.0M$105.2M
Free cash flow$513.1M$744.4M$70.9M−$112.1M−$83.0M
Cash$802.8M$292.9M$118.9M$98.3M$169.8M
Debt$1.0M$2.64B$2.41B$2.48B$2.65B
Shares outstanding41.7M66.4M66.7M67.3M67.9M